For people living with T1DM, parents of children with T1DM, and those newly diagnosed.
At a Glance
| Medical name | Type 1 Diabetes Mellitus (T1DM) / Insulin-Dependent Diabetes |
| ICD-10 code | E10 |
| What it is | Autoimmune destruction of insulin-producing beta cells in the pancreas. Requires lifelong insulin from diagnosis. |
| How common | ~100,000–150,000 South Africans; 5-fold increase in SA children and adolescents 2011–2021 |
| Chronic Disease List | CDL 011 — all schemes must fund insulin and monitoring at PMB level |
| CDL baseline insulin | NPH (isophane) insulin + regular insulin — the PMB-funded standard |
| Annual management cost | R16,500 (CDL baseline, no CGM) to R70,000+ (modern analog insulin + CGM + pump) |
| Main financial risk | DKA admission (~R35,000); specialist shortfall; OOP cost of analog insulin and CGM not fully funded by CDL |
Understanding Type 1 Diabetes
Type 1 diabetes is an autoimmune disease. The immune system destroys the beta cells in the pancreas that produce insulin. Without insulin, glucose cannot enter cells to produce energy, and blood glucose rises to dangerous levels. This is fundamentally different from Type 2 diabetes: T1DM is not caused by diet or lifestyle, and it cannot be managed with oral medications alone. Insulin is required from the moment of diagnosis, for life.
T1DM typically presents in childhood, adolescence, or young adulthood — though adult-onset T1DM (LADA — Latent Autoimmune Diabetes in Adults) also occurs. The classic presentation is rapid onset: days to weeks of excessive thirst, excessive urination, unexplained weight loss, and fatigue. Many patients in sub-Saharan Africa (20–80%, per published studies) present in diabetic ketoacidosis (DKA) at the time of initial diagnosis.
The Sub-Saharan Africa Context
T1DM incidence is rising rapidly in Africa. A 2023 Frontiers in Public Health study reported a 5-fold increase in children and adolescents with T1DM in sub-Saharan Africa between 2011 and 2021. Access to insulin, blood glucose monitoring, and specialist care is a critical equity issue in SA — particularly in the public sector.
A landmark finding from South African research (SAMJ, 2021): the cost of a single preventable DKA hospital admission equalled approximately 27 years of insulin therapy at 2015 prices. Prevention — through access to insulin, monitoring, and education — is dramatically more cost-effective than managing the emergency.
Treatment in South Africa
All T1DM management is insulin-based. There is no oral medication equivalent for T1DM. The regime is lifelong.
CDL Baseline: NPH + Regular Insulin
The PMB CDL formulary for T1DM funds NPH (isophane, intermediate-acting) insulin twice daily and regular (short-acting) insulin before meals. This is the publicly funded standard across SA. It is effective but requires rigid meal timing and carries a higher nocturnal hypoglycaemia risk compared to modern analog insulin regimes.
Modern Standard of Care: Basal-Bolus Analog Insulin
Insulin analogs are more predictable, more flexible, and associated with better glucose control and fewer hypoglycaemic episodes: - Basal (long-acting) analog: Insulin glargine (Lantus/generic) or detemir (Levemir) — once daily - Rapid-acting analog: Insulin aspart (NovoRapid), glulisine (Apidra), or lispro (Humalog) — with each meal
Analog insulin is NOT in the standard PMB CDL formulary. Most patients require clinical motivation for scheme funding of analogs.
Medication and Monitoring Cost Table (2026 Estimates)
| Item | Monthly Cost | CDL Funded |
|---|---|---|
| NPH insulin (CDL baseline) | ~R250 | Yes |
| Regular insulin (CDL baseline) | ~R200 | Yes |
| Insulin glargine (generic, modern standard) | ~R950 | Scheme-dependent (motivation required) |
| Insulin aspart/lispro (rapid analog) | ~R900 | Scheme-dependent (motivation required) |
| Blood glucose strips (SMBG, 4–8 tests/day) | ~R600 | Partially (PMB quantity limited) |
| FreeStyle Libre 2 CGM sensors | ~R900 | NOT standard CDL; scheme-dependent |
| Dexcom G7 CGM sensors | ~R1,400 | NOT standard CDL; scheme-dependent |
All costs are 2026 SEP estimates pending SAHPRA verification.
Annual Cost Breakdown
| Scenario | Medication | Monitoring | Visits | Total |
|---|---|---|---|---|
| CDL baseline (NPH + regular, SMBG strips only) | R5,400 | R7,200 (strips) | R3,280 | ~R16,500 |
| Modern (analog insulin + Libre 2 CGM) | R22,200 | R10,800 (CGM) | R3,280 | ~R37,500 |
| Complex (analogs + Dexcom + pump consumables) | R22,200 | R16,800 (CGM) + R14,400 (pump) | R3,600 | ~R61,000 |
Blood glucose strips alone cost R7,200/year — the largest single line item in the CDL-funded scenario.
Your Medical Aid and Type 1 Diabetes
What your scheme must fund (CDL 011)
All registered schemes must fund: - NPH insulin + regular insulin - Blood glucose strips (a specified monthly quantity — varies by scheme) - GP management consultations - HbA1c testing (3-monthly) - Annual comprehensive diabetes review (including kidney function, urine albumin, eye examination, foot examination) - Dietitian or CDE (Certified Diabetes Educator) consultation — as per CDL algorithm
What most schemes do NOT fund as standard
- Insulin analogs (glargine, aspart, lispro, detemir) — require clinical motivation
- CGM sensors (FreeStyle Libre, Dexcom) — except where scheme has specific T1DM CGM benefit
- Insulin pump (CSII) hardware — exceptional needs only (~R45,000 device)
- Insulin pump consumables — if pump funded, consumables typically funded too
- Extra glucose strips beyond PMB allocation
Key differences between schemes for T1DM
T1DM is the chronic condition where scheme selection has the most material impact on actual annual OOP spending. Key questions to evaluate:
- Does the scheme fund insulin analogs on CDL motivation?
- Does the scheme fund CGM sensors for T1DM patients?
- What is the PMB monthly allocation of glucose strips?
- Does the scheme have a CDE programme for T1DM?
- Does the scheme fund insulin pump hardware for exceptional cases?
The Gap Cover Question
Daily management: OOP exposure is from analog insulin and CGM sensors not funded by CDL. This is NOT closed by gap cover — it's a scheme formulary issue, not a specialist shortfall issue.
Hospital admissions (DKA): DKA requires emergency hospital admission with endocrinologist/internist management. In a private hospital, endocrinologist shortfall on a DKA admission can be R5,000–R25,000. Gap cover closes this.
The critical advisory insight: For T1DM patients, the two most important decisions are (1) scheme selection — choose a scheme that funds analog insulin and ideally CGM, and (2) gap cover — for the DKA risk. Both matter. The OOP medication burden and the hospitalisation risk are distinct problems requiring distinct solutions.
South African Sources
- The phenotype of type 1 diabetes in sub-Saharan Africa. Frontiers in Public Health, 2023
- A total cost perspective of T1DM and T2DM in two South African medical schemes. SAMJ, 2021
- Health care resource utilisation in adults with T1DM in the SA public health sector. PMC9983812, 2023
- Mapping the storm: diabetic emergencies in Africa. Frontiers in Clinical Diabetes and Healthcare, 2026
- Council for Medical Schemes: CDL 011 PMB Algorithm
Check your T1DM cover on AURA →
Medical disclaimer: Educational purposes only. All medication costs are 2026 estimates pending SAHPRA SEP verification. T1DM management should always be directed by a doctor or endocrinologist.